PE20140968A1 - Derivados de benzamida sustituida - Google Patents
Derivados de benzamida sustituidaInfo
- Publication number
- PE20140968A1 PE20140968A1 PE2013002778A PE2013002778A PE20140968A1 PE 20140968 A1 PE20140968 A1 PE 20140968A1 PE 2013002778 A PE2013002778 A PE 2013002778A PE 2013002778 A PE2013002778 A PE 2013002778A PE 20140968 A1 PE20140968 A1 PE 20140968A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- fluor
- cyane
- urea
- benzamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE LA FORMULA (I), EN LA QUE R1 ES HIDROGENO, HALOGENO, CIANO, ENTRE OTROS; n ES EL NUMERO 1, 2; R2 ES HALOGENO, CIANO, ENTRE OTROS; R3 ES H; X ES UN ENLACE, -NR�-, -CH2NH-, -CHR�-; R� ES HIDROGENO, ALQUILO C1-C7; Z ES UN ENLACE, -CH2- , -O-; AR ES FENILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 1-(3-CIANO-FENIL)-3-((R) -2-FLUOR-4-MORFOLIN-2-IL-FENIL-UREA, 1-(3-CIANO-FENIL) -3-((S)-2-FLUOR-4-MORFOLIN-2-IL-FENIL)-UREA, 1-(3-CIANO-5-FLUOR-FENIL)-3-((S)-2-FLUOR-4-MORFOLIN-2-IL-FENIL)- UREA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA, SIENDO UTIL EN EL TRATAMIENTO DE LA DEPRESION, LOS TRASTORNOS DE ANSIEDAD, ENTRE OTROS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169441 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140968A1 true PE20140968A1 (es) | 2014-08-06 |
Family
ID=46298391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002778A PE20140968A1 (es) | 2011-06-10 | 2012-06-06 | Derivados de benzamida sustituida |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9029370B2 (es) |
| EP (1) | EP2718271B1 (es) |
| JP (1) | JP5788087B2 (es) |
| KR (1) | KR101574906B1 (es) |
| CN (1) | CN103596937B (es) |
| AR (1) | AR086880A1 (es) |
| AU (1) | AU2012266462B2 (es) |
| BR (1) | BR112013030698B1 (es) |
| CA (1) | CA2834675C (es) |
| CL (1) | CL2013003485A1 (es) |
| CO (1) | CO6811866A2 (es) |
| CY (1) | CY1116769T1 (es) |
| DK (1) | DK2718271T3 (es) |
| EA (1) | EA022376B1 (es) |
| EC (1) | ECSP13013073A (es) |
| ES (1) | ES2546529T3 (es) |
| HK (1) | HK1192562A1 (es) |
| HR (1) | HRP20151201T1 (es) |
| IL (1) | IL229335A (es) |
| MA (1) | MA35194B1 (es) |
| MX (1) | MX354410B (es) |
| MY (1) | MY162461A (es) |
| PE (1) | PE20140968A1 (es) |
| PL (1) | PL2718271T3 (es) |
| PT (1) | PT2718271E (es) |
| RS (1) | RS54415B1 (es) |
| SG (1) | SG194840A1 (es) |
| SI (1) | SI2718271T1 (es) |
| TW (1) | TWI445701B (es) |
| UA (1) | UA110388C2 (es) |
| WO (1) | WO2012168265A1 (es) |
| ZA (1) | ZA201308401B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| ES2554843T3 (es) * | 2012-01-12 | 2015-12-23 | F. Hoffmann-La Roche Ag | Derivados heterocíclicos como receptores asociados de trazas de amina (TAARs) |
| KR101706486B1 (ko) * | 2012-09-14 | 2017-02-13 | 에프. 호프만-라 로슈 아게 | 우울증, 당뇨병 및 파킨슨병과 같은 몇가지 장애의 치료에 사용하기 위한 taar 조절제로서의 피라졸 카복스아마이드 유도체 |
| CN104603129A (zh) * | 2012-09-17 | 2015-05-06 | 霍夫曼-拉罗奇有限公司 | 三唑甲酰胺衍生物 |
| CN104768950A (zh) * | 2012-11-07 | 2015-07-08 | 霍夫曼-拉罗奇有限公司 | 吡嗪衍生物 |
| WO2015165085A1 (en) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Morpholin-pyridine derivatives |
| TR201808506T4 (tr) * | 2014-05-28 | 2018-07-23 | Hoffmann La Roche | Taar1 modülatörleri olarak 5-oksa-2-azabisiklo[2.2.2]oktan-4-il ve 5-oksa-2-azabisiklo[2.2.1]heptan-4-il türevleri. |
| CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
| KR102415797B1 (ko) * | 2016-03-17 | 2022-07-04 | 에프. 호프만-라 로슈 아게 | Taar의 작용제로서 활성을 갖는 5-에틸-4-메틸-피라졸-3-카복스아미드 유도체 |
| WO2021005137A1 (en) * | 2019-07-11 | 2021-01-14 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted pyrazole derivatives |
| BR112022017099A2 (pt) * | 2020-02-28 | 2022-11-16 | Univ Texas | Composto, composição farmacêutica, método para inibição de ripk1, método para tratamento de uma doença mediada por ripk1 e método para tratamento de lesão no snc |
| WO2024118488A1 (en) * | 2022-11-28 | 2024-06-06 | Sumitomo Pharma America, Inc. | 2-phenylmorpholine and 2-phenyl(thio)morpholine compounds and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| IL136388A0 (en) | 1997-12-04 | 2001-06-14 | Allergan Sales Inc | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors |
| AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| WO2008026046A1 (en) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Morpholine d3 dopamine antagonists |
| CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| AU2008209672B2 (en) | 2007-02-02 | 2011-02-10 | Novartis Ag | Chromene S1P1 receptor antagonist |
| CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
| CA2695071A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
| UY32858A (es) | 2009-08-31 | 2011-03-31 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina como moduladores de sip |
| HUE043522T2 (hu) | 2009-09-04 | 2019-08-28 | Biogen Ma Inc | Bruton tirozinkináz inhibitorok |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9073911B2 (en) | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
-
2012
- 2012-06-01 US US13/485,993 patent/US9029370B2/en active Active
- 2012-06-06 JP JP2014514044A patent/JP5788087B2/ja active Active
- 2012-06-06 RS RS20150747A patent/RS54415B1/en unknown
- 2012-06-06 BR BR112013030698-0A patent/BR112013030698B1/pt active IP Right Grant
- 2012-06-06 EA EA201391815A patent/EA022376B1/ru not_active IP Right Cessation
- 2012-06-06 PL PL12727633T patent/PL2718271T3/pl unknown
- 2012-06-06 CN CN201280028534.4A patent/CN103596937B/zh active Active
- 2012-06-06 WO PCT/EP2012/060637 patent/WO2012168265A1/en active Application Filing
- 2012-06-06 DK DK12727633.5T patent/DK2718271T3/en active
- 2012-06-06 PE PE2013002778A patent/PE20140968A1/es active IP Right Grant
- 2012-06-06 ES ES12727633.5T patent/ES2546529T3/es active Active
- 2012-06-06 KR KR1020147000701A patent/KR101574906B1/ko active IP Right Grant
- 2012-06-06 AU AU2012266462A patent/AU2012266462B2/en active Active
- 2012-06-06 CA CA2834675A patent/CA2834675C/en active Active
- 2012-06-06 PT PT127276335T patent/PT2718271E/pt unknown
- 2012-06-06 EP EP12727633.5A patent/EP2718271B1/en active Active
- 2012-06-06 MX MX2013014371A patent/MX354410B/es active IP Right Grant
- 2012-06-06 SI SI201230320T patent/SI2718271T1/sl unknown
- 2012-06-06 UA UAA201400121A patent/UA110388C2/ru unknown
- 2012-06-06 SG SG2013082656A patent/SG194840A1/en unknown
- 2012-06-06 MY MYPI2013003963A patent/MY162461A/en unknown
- 2012-06-07 TW TW101120551A patent/TWI445701B/zh active
- 2012-06-08 AR ARP120102045A patent/AR086880A1/es unknown
-
2013
- 2013-11-07 ZA ZA2013/08401A patent/ZA201308401B/en unknown
- 2013-11-07 IL IL229335A patent/IL229335A/en active IP Right Grant
- 2013-11-29 CO CO13281375A patent/CO6811866A2/es active IP Right Grant
- 2013-12-05 CL CL2013003485A patent/CL2013003485A1/es unknown
- 2013-12-10 EC ECSP13013073 patent/ECSP13013073A/es unknown
- 2013-12-18 MA MA36585A patent/MA35194B1/fr unknown
-
2014
- 2014-06-20 HK HK14105919.1A patent/HK1192562A1/zh unknown
-
2015
- 2015-10-06 CY CY20151100894T patent/CY1116769T1/el unknown
- 2015-11-09 HR HRP20151201TT patent/HRP20151201T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140968A1 (es) | Derivados de benzamida sustituida | |
| PE20142282A1 (es) | Nuevos derivados de aril-quinolina | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| PE20140934A1 (es) | Derivados de pirazol | |
| EA200901379A1 (ru) | Производные никотиновой кислоты как модуляторы метаботропных глутаматных рецепторов 5 подтипа | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20130311A1 (es) | Composiciones y metodos para modular la via de senalizacion de wnt | |
| PE20141996A1 (es) | Compuestos con actividad nematicida | |
| NI201000109A (es) | Derivados bis-(sulfonilamino) para uso en terapia. | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| WO2007022934A3 (en) | Azabicyclo (3, 1, 0) hexan derivatives useful as modulators of dopamine d3 receptors | |
| CO6280476A2 (es) | Derivados de alcanos azabiciclicos sustituidos con biarilo como moduladores de la actividad de los receptores nicotinicos de acetilcolina | |
| UY30897A1 (es) | Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| UA109525C2 (xx) | Алкіламідна сполука і її застосування | |
| AR074817A1 (es) | Dihidropiridona-amidas como moduladores de p2x7 | |
| RS51661B (en) | NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM | |
| AR071925A1 (es) | Malonamidas como antagonistas de orexina | |
| AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| UY29184A1 (es) | Derivados de sulfonilbencimidazol | |
| ECSP088257A (es) | Derivados de amida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |